SMITH+NEPHEW UNVEILS EXPANDED SPORTS MEDICINE PORTFOLIO AT AAOS 2024

Smith+Nephew announced the premiere of its newly acquired CARTIHEAL AGILI-C Cartilage Repair Implant alongside the REGENETEN Bioinductive Implant at the AAOS Annual Meeting, demonstrating its leadership with products that enable biological healing for Sports Medicine. Backed by impressive clinical evidence, both technologies are transforming the way healthcare professionals treat soft tissue repair and helping improve patient outcomes versus the current standard of care.

The CARTIHEAL AGILI-C implant is an accessible, one-step treatment for osteochondral (bone and cartilage) lesions that do not require donor tissue. It is indicated to treat a broad patient population, including traumatic, osteoarthritic and the approximately 700,000 individuals who receive cartilage repair annually in the US. The implant has demonstrated proven superiority with twice the pain reduction versus the current standard of care and has the potential to transform cartilage repair outcomes.

During its development, the CARTIHEAL AGILI-C implant received breakthrough designation status by the United States Food and Drug Administration – expedited review and approval for a product that could provide more effective treatment than existing alternatives and in the best interest of patients. It received premarket approval in 2022 and is now commercially available for sale in the US.

REGENETEN Bioinductive Implant – changing the game in rotator cuff repair and expanding applications
With more than 100,000 procedures completed globally since its introduction in 2014, the REGENETEN Bioinductive Implant has had a massive impact, offering a potentially better solution for more than 1 million people having surgery for tendon injuries each year. The collagen-based implant supports the body’s natural healing response to facilitate the formation of new tendon-like tissue to biologically augment the existing tendon and change the course of disease progression.

A recently completed randomized controlled trial published in December 2023, concluded that at one year, re-tear rates for medium and large full-thickness rotator cuff tears repaired and augmented with the REGENETEN Bioinductive Implant were reduced by 68%.

The REGENETEN Bioinductive Implant is similarly redefining healing potential for Achilles injuries when used to augment insertional or midsubstance Achilles repair. The implant creates an environment that is conducive to healing and induces tendon-like tissue growth. When coupling the unique properties of the REGENETEN Bioinductive Implant with Smith+Nephew’s new procedural offerings for Achilles injuries, the solution is unmatched within the Foot and Ankle segment.